+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)
Global Polycystic Kidney Disease Drugs Market 2019-2023 - Product Image

Global Polycystic Kidney Disease Drugs Market 2019-2023

  • ID: 4792920
  • Report
  • Region: Global
  • 125 pages
  • TechNavio
1h Free Analyst Time

Speak directly to the analyst to clarify any post sales queries you may have.

1 of 4

FEATURED COMPANIES

  • Merck & Co., Inc.
  • Otsuka Holdings Co. Ltd.
  • Sanofi.
  • MORE
Global Polycystic Kidney Disease Drugs Market: About this market

Polycystic kidney disease is a genetic disorder in which clusters of cysts develop primarily within the kidneys, causing kidneys to enlarge and lose function over time. This polycystic kidney disease drugs market analysis considers the revenue generation from both autosomal dominant polycystic kidney disease (ADPKD), and autosomal recessive polycystic kidney disease (ARPKD). Our analysis also considers the sales of polycystic kidney disease drugs in North America, Europe, Asia, and ROW. In 2018, the ARPKD segment had a significant market share, and this trend is expected to continue over the forecast period. Factors such as the growing prevalence of the disease will play a significant role in the ARPKD segment to maintain its market position. Our global polycystic kidney disease drugs market report looks at factors such as the high prevalence of chronic kidney diseases, special regulatory designations, and the increasing R&D for developing new drugs. However, the lack of approved drugs, availability of substitute treatment options, and stringent regulations may hamper the growth of the polycystic kidney disease drugs industry over the forecast period.

Global polycystic kidney disease drugs market: Overview

Special regulatory designations

The growing focus on developing and evaluating drugs that effectively cure and diagnose rare diseases is encouraging organizations such as the US FDA and EMA to provide special regulatory designations to underlying companies. This provides companies with benefits such as tax credits for clinical trials and protocol assistance. These designations help vendors to easily launch drugs, which will help them in generating revenues. Thus, the special regulatory designations will fuel the growth of the polycystic kidney disease drugs market at a CAGR of more than 6% during the forecast period.

Favorable reimbursement policies

The high cost of off-label drugs and the approved novel drug for the treatment of polycystic kidney disease makes it challenging for patients to afford it. Hence, government and non-government organizations are introducing reimbursement policies to help patients in availing the treatment. These policies are further encouraging vendors to increase investments in R&D. Thus, the presence of favorable reimbursement policies will fuel the growth of the market.

Competitive Landscape

With the presence of several major players, the global polycystic kidney disease drugs market is moderately fragmented. This robust vendor analysis is designed to help clients improve their market position, and in line with this, this report provides a detailed analysis of several leading polycystic kidney disease drugs providers, that include Johnson & Johnson Services Inc., Merck & Co., Inc., Otsuka Holdings Co. Ltd., Reata Pharmaceuticals Inc., and Sanofi.

Also, the polycystic kidney disease drugs market analysis report includes information on upcoming trends and challenges that will influence market growth. This is to help companies strategize and leverage on all forthcoming growth opportunities.
Note: Product cover images may vary from those shown
2 of 4

FEATURED COMPANIES

  • Merck & Co., Inc.
  • Otsuka Holdings Co. Ltd.
  • Sanofi.
  • MORE
PART 01: EXECUTIVE SUMMARY

PART 02: SCOPE OF THE REPORT
  • Preface
  • Currency conversion rates for US$
PART 03: MARKET LANDSCAPE
  • Market ecosystem
  • Market characteristics
  • Market segmentation analysis
PART 04: MARKET SIZING
  • Market definition
  • Market sizing 2018
  • Market size and forecast 2018-2023
PART 05: FIVE FORCES ANALYSIS
  • Bargaining power of buyers
  • Bargaining power of suppliers
  • Threat of new entrants
  • Threat of substitutes
  • Threat of rivalry
  • Market condition
PART 06: PIPELINE ANALYSIS

PART 07: MARKET SEGMENTATION BY TYPE
  • Market segmentation by type
  • Comparison by type
  • ADPKD - Market size and forecast 2018-2023
  • ARPKD - Market size and forecast 2018-2023
  • Market opportunity by type
PART 08: CUSTOMER LANDSCAPE

PART 09: GEOGRAPHIC LANDSCAPE
  • Geographic segmentation
  • Geographic comparison
  • North America - Market size and forecast 2018-2023
  • Europe - Market size and forecast 2018-2023
  • Asia - Market size and forecast 2018-2023
  • ROW - Market size and forecast 2018-2023
  • Key leading countries
  • Market opportunity
PART 10: DECISION FRAMEWORK

PART 11: DRIVERS AND CHALLENGES
  • Market drivers
  • Market challenges
PART 12: MARKET TRENDS
  • Increasing research funding
  • Favorable reimbursement policies
  • Growing awareness about kidney diseases
PART 13: VENDOR LANDSCAPE
  • Overview
  • Landscape disruption
  • Competitive scenario
PART 14: VENDOR ANALYSIS
  • Vendors covered
  • Vendor classification
  • Market positioning of vendors
  • Johnson & Johnson Services Inc.
  • Merck & Co., Inc.
  • Otsuka Holdings Co. Ltd.
  • Reata Pharmaceuticals Inc.
  • Sanofi
PART 15: APPENDIX
  • Research methodology
  • List of abbreviations
  • Definition of market positioning of vendors
PART 16: EXPLORE

List of Exhibits:
Exhibit 01: Global pharmaceuticals market
Exhibit 02: Segments of global pharmaceuticals market
Exhibit 03: Market characteristics
Exhibit 04: Market segments
Exhibit 05: Market definition - Inclusions and exclusions checklist
Exhibit 06: Market size 2018
Exhibit 07: Global market: Size and forecast 2018-2023 ($ millions)
Exhibit 08: Global market: Year-over-year growth 2019-2023 (%)
Exhibit 09: Five forces analysis 2018
Exhibit 10: Five forces analysis 2023
Exhibit 11: Bargaining power of buyers
Exhibit 12: Bargaining power of suppliers
Exhibit 13: Threat of new entrants
Exhibit 14: Threat of substitutes
Exhibit 15: Threat of rivalry
Exhibit 16: Market condition - Five forces 2018
Exhibit 17: Some of the clinical stage drugs for polycystic kidney disease
Exhibit 18: Type - Market share 2018-2023 (%)
Exhibit 19: Comparison by type
Exhibit 20: ADPKD - Market size and forecast 2018-2023 ($ millions)
Exhibit 21: ADPKD - Year-over-year growth 2019-2023 (%)
Exhibit 22: ARPKD - Market size and forecast 2018-2023 ($ millions)
Exhibit 23: ARPKD - Year-over-year growth 2019-2023 (%)
Exhibit 24: Market opportunity by type
Exhibit 25: Customer landscape
Exhibit 26: Market share by geography 2018-2023 (%)
Exhibit 27: Geographic comparison
Exhibit 28: North America - Market size and forecast 2018-2023 ($ millions)
Exhibit 29: North America - Year-over-year growth 2019-2023 (%)
Exhibit 30: Top 3 countries in North America
Exhibit 31: Europe - Market size and forecast 2018-2023 ($ millions)
Exhibit 32: Europe - Year-over-year growth 2019-2023 (%)
Exhibit 33: Top 3 countries in Europe
Exhibit 34: Asia - Market size and forecast 2018-2023 ($ millions)
Exhibit 35: Asia - Year-over-year growth 2019-2023 (%)
Exhibit 36: Top 3 countries in Asia
Exhibit 37: ROW - Market size and forecast 2018-2023 ($ millions)
Exhibit 38: ROW - Year-over-year growth 2019-2023 (%)
Exhibit 39: Top 3 countries in ROW
Exhibit 40: Key leading countries
Exhibit 41: Market opportunity
Exhibit 42: Prevalence of chronic kidney diseases per 100 people
Exhibit 43: Impact of drivers and challenges
Exhibit 44: Vendor landscape
Exhibit 45: Landscape disruption
Exhibit 46: Vendors covered
Exhibit 47: Vendor classification
Exhibit 48: Market positioning of vendors
Exhibit 49: Johnson & Johnson Services Inc. - Vendor overview
Exhibit 50: Johnson & Johnson Services Inc. - Business segments
Exhibit 51: Johnson & Johnson Services Inc. - Organizational developments
Exhibit 52: Johnson & Johnson Services Inc. - Geographic focus
Exhibit 53: Johnson & Johnson Services Inc. - Segment focus
Exhibit 54: Johnson & Johnson Services Inc. - Key offerings
Exhibit 55: Johnson & Johnson Services Inc. - Key customers
Exhibit 56: Merck & Co. Inc. - Vendor overview
Exhibit 57: Merck & Co. Inc. - Business segments
Exhibit 58: Merck & Co. Inc. - Organizational developments
Exhibit 59: Merck & Co. Inc. - Geographic focus
Exhibit 60: Merck & Co. Inc. - Segment focus
Exhibit 61: Merck & Co. Inc. - Key offerings
Exhibit 62: Merck & Co. Inc. - Key customers
Exhibit 63: Otsuka Holdings Co. Ltd. - Vendor overview
Exhibit 64: Otsuka Holdings Co. Ltd. - Business segments
Exhibit 65: Otsuka Holdings Co. Ltd. - Organizational developments
Exhibit 66: Otsuka Holdings Co. Ltd. - Geographic focus
Exhibit 67: Otsuka Holdings Co. Ltd. - Segment focus
Exhibit 68: Otsuka Holdings Co. Ltd. - Key offerings
Exhibit 69: Otsuka Holdings Co. Ltd. - Key customers
Exhibit 70: Reata Pharmaceuticals Inc. - Vendor overview
Exhibit 71: Reata Pharmaceuticals Inc. - Organizational developments
Exhibit 72: Reata Pharmaceuticals Inc. - Key offerings
Exhibit 73: Reata Pharmaceuticals Inc. - Key customers
Exhibit 74: Sanofi - Vendor overview
Exhibit 75: Sanofi - Business segments
Exhibit 76: Sanofi - Organizational developments
Exhibit 77: Sanofi - Geographic focus
Exhibit 78: Sanofi - Segment focus
Exhibit 79: Sanofi - Key offerings
Exhibit 80: Sanofi - Key customers
Exhibit 81: Validation techniques employed for market sizing
Exhibit 82: Definition of market positioning of vendors
Note: Product cover images may vary from those shown
3 of 4

Loading
LOADING...

4 of 4

FEATURED COMPANIES

  • Merck & Co., Inc.
  • Otsuka Holdings Co. Ltd.
  • Sanofi.
  • MORE
The following companies are recognised as the key players in the global polycystic kidney disease drugs market: Johnson & Johnson Services Inc., Merck & Co., Inc., Otsuka Holdings Co. Ltd., Reata Pharmaceuticals Inc., and Sanofi.

Commenting on the report, an analyst from the research team said: “The latest trend gaining momentum in the market is the favorable reimbursement policies.”

According to the report, one of the major drivers for this market is the special regulatory designations.

Further, the report states that one of the major factors hindering the growth of this market is the availability of substitute treatment options.

The study was conducted using an objective combination of primary and secondary information including inputs from key participants in the industry. The report contains a comprehensive market and vendor landscape in addition to a SWOT analysis of the key vendors.
Note: Product cover images may vary from those shown
5 of 4
  • Johnson & Johnson Services Inc.
  • Merck & Co., Inc.
  • Otsuka Holdings Co. Ltd.
  • Reata Pharmaceuticals Inc.
  • Sanofi.
Note: Product cover images may vary from those shown
Order Online - visit: https://www.researchandmarkets.com/reports/4792920
Adroll
adroll